Brief: Veracyte Q1 Revenue USD 114.5 Million Vs. IBES Estimate USD 111.1 Million
07/05/2025 21:05
May 07 (Reuters) - Veracyte Q1 adjusted operating expenses USD 60.5 million. Q1 net income USD 7 million Q1 gross margin 69% outlook FY revenue USD 470-480 million
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina